Honoré S, Trillard M, Ould-Hocine Z, Lesprit P, Deforges L, Legrand P
Laboratoire de microbiologie-virologie-hygiène, hôpital Henri-Mondor, 51, avenue du Maréchal-de-Lattre-de-Tassigny, 94010 Créteil cedex, France.
Pathol Biol (Paris). 2004 Oct;52(8):429-33. doi: 10.1016/j.patbio.2004.07.026.
Bacteriological confirmation of pneumonia (PNM) in hospitalized patients is often erratic or belated. Because of importance of prognosis, early adaptation of treatment requires an empirical antimicrobial therapy (generally aminopenicillin and macrolide combination). The starting therapeutic strategy should profit by a fast and reliable test asserting a pneumococcal etiology. The Binax Now S. pneumoniae (BNP) test allows an urinary pneumococcal antigen (UPA) detection using an immunochromatographic membrane assay within 15 minutes.
We first evaluated the BNP test for 28 patients with pneumococcal PNM proved by culture, and 118 negative control patients without PNM. The BNP test was then evaluated by testing urine from 158 hospitalized patients with a clinical picture of PNM (community-acquired: 90, nosocomial: 68) for whom a research of urinary Legionella antigen (Binax Now) was prescribed and was positive for only two cases. 57 patients (36.1%) were hospitalized in ICU.
The sensitivity was 71.4% (85.7% for the 21 bacteriemic PNM), and the specificity was 98.3%; that is consistent with previous published data. Among the 158 patients with PNM, UPA was detected in 17 cases (10.8%): 15 within the community-acquired PNM (16.7%) and 2 (2.9%) within the nosocomial cases. The pneumococcal etiology was confirmed by bacteriological samples in 7/17 patients (6 by blood cultures). The 10 others showed clinical and radiological features in agreement with a pneumococcal PNM. Among the 141 patients with negative AUP, S. pneumoniae was isolated from 6 of them (2 in blood cultures).
The Binax Now S. pneumoniae test allowed a fast and reliable etiological diagnosis in 10.8% of hospitalized PNM (16.7% of the community-acquired cases) having a research of urinary Legionella antigen (conceiving with severity factors). So it could conduce to an improved adjustment of the starting antimicrobial therapy of hospitalized adult patients with PNM.
住院患者肺炎(PNM)的细菌学确诊往往不稳定或延迟。鉴于预后的重要性,早期调整治疗需要经验性抗菌治疗(通常是氨苄青霉素和大环内酯类药物联合使用)。起始治疗策略应借助快速可靠的检测来确定肺炎球菌病因。Binax Now肺炎链球菌(BNP)检测可在15分钟内通过免疫层析膜分析法检测尿肺炎球菌抗原(UPA)。
我们首先对28例经培养证实为肺炎球菌性PNM的患者以及118例无PNM的阴性对照患者进行了BNP检测。然后,对158例有PNM临床表现的住院患者(社区获得性:90例,医院获得性:68例)的尿液进行检测,对这些患者进行了尿军团菌抗原检测(Binax Now),仅2例呈阳性。57例患者(36.1%)入住重症监护病房。
敏感性为71.4%(21例菌血症性PNM患者的敏感性为85.7%),特异性为98.3%;这与先前发表的数据一致。在158例PNM患者中,17例(10.8%)检测到UPA:社区获得性PNM患者中有15例(16.7%),医院获得性病例中有2例(2.9%)。17例患者中有7例(6例通过血培养)的细菌学样本证实为肺炎球菌病因。其余10例患者的临床和影像学特征与肺炎球菌性PNM相符。在141例AUP阴性的患者中,有6例分离出肺炎链球菌(2例血培养阳性)。
Binax Now肺炎链球菌检测能够对10.8%具有尿军团菌抗原检测(结合严重程度因素)的住院PNM患者(社区获得性病例的16.7%)进行快速可靠的病因诊断。因此,它有助于改善住院成年PNM患者起始抗菌治疗的调整。